Chandler Park, MD introduces a renal cell carcinoma (RCC) patient case, sharing his initial impressions and discussing treatment approaches.
A 51-Year-Old Man with Renal Cell Carcinoma
An overview of the KEYNOTE-564 study design followed by an analysis of 30-month follow-up data presented at the 2022 ASCO Genitourinary Cancers Symposium.
Thoughtful discussion of ongoing clinical trials in the renal cell carcinoma landscape, with a particular focus on their eventual clinical implications.
Chandler Park, MD shares clinical insights regarding care for patients with renal cell carcinoma, touching on treatment selection and managing adverse effects.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
